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Effective treatments are not yet available for the majority 
of stroke patients despite the significant advances in acute 
stroke management and care evident since the advent of 
therapeutic recanalization in 2015. Unfortunately, even 
patients who are eligible for recanalization treatment often 
suffer from residual functional deficits. Hence, there is an 
unmet demand for additional stroke therapies promoting 
functional recovery, not only those that can be considered 
as complementary approaches to recanalization but also 
for treatments that can be provided beyond its narrow 
time window. Cell therapies are an emerging paradigm 
in translational neuroscience and have been widely 
investigated in experimental stroke models (1). Preclinical 
evidence collected over the past two decades has revealed 
that administration of cells can exert robust effects in 
improving functional outcome when delivered in subacute 
(2,3) and even in chronic stroke stages (4). These promising 
findings have promoted small, early phase clinical studies 
intended to assess the feasibility, safety and efficacy of cell 
therapy approaches (5). 
Primary versus secondary endpoints in early-
stage clinical trials
The most important efficacy endpoints in clinical trials 
are functional outcome and a reduction in the size of the 
ischemic lesion, but both of these parameters typically 
exhibit considerable inter-individual variations. Although 
being invaluable to move the field forward, many of these 
early-stage clinical trials have been uncontrolled or simply 
underpowered to assess efficacy endpoints in a reliable 
manner. Budgetary and time constraints nevertheless 
force industrial sponsors to include some kinds of efficacy 
endpoints despite power limits, even though it is evident 
that the trials may potentially miss all but the largest 
sized effects. In the worst case scenario, the progress of a 
potentially effective and clinically relevant experimental 
therapy may be discontinued due to the failure to achieve 
some pre-determined level of statistical significance in an 
early-stage trial. 
The RECOVER-Stroke study: novel design 
features
The recent randomized, sham-controlled, multi-center 
clinical RECOVER-Stroke study conducted by Savitz 
et al. (6) successfully avoids these risks by strictly defining 
and following primary and secondary safety endpoints. The 
study featured an impressive array of safety endpoints and 
stratified patients according to NIHSS scores (≤15 versus 
≥16) and whether the patients suffered from a lacunar versus 
a cortical stroke. Importantly, this study also represents the 
first serious attempt to assess the safety of cell delivery by 
the intra-arterial route in stroke patients. Altogether 48 
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patients were recruited. Initially recruitment of up to 100 
patients had been planned, but the trial was stopped after 
an interim repowering analysis revealed that the number 
of enrolled patients was already sufficient to prove safety. 
This again highlights the clever design of this clinical 
investigation, being different from many other studies 
which have often defined efficacy endpoints as secondary 
but subsequently re-defined them as primary endpoints.
Characterization of the used cell product
A special subpopulation of bone marrow cells that express 
high levels of aldehyde dehydrogenase (ALDH) was 
administered in the trial. These cells, which were available 
as the commercial ALD-401 cell product, were selected 
for CD34+ and CD133+ stem and progenitor cell surface 
markers but are depleted of stem and progenitor cells which 
are present in unselected populations such as umbilical cord 
blood or bone marrow mononuclear cells. Nevertheless, 
ALDH cells still represent a heterogeneous population 
containing hematopoietic, endothelial, mesenchymal and 
potentially neural progenitor cells (7). Previously, ALDH 
cells have been reported to promote repair processes in 
experimental models of cardiovascular disease and limb 
ischemia (7). However, the exact therapeutic mechanisms 
are not entirely clear, which has also been the case for many 
other cell products. Cells expressing high levels of ALDH 
may be more resilient to insults, increasing their survival 
in hostile tissue environments (8) such as are present in the 
brain after a stroke. In fact, it might be advantageous that 
ALDH cells contain diverse cell types, as the different cells 
may be able to exert beneficial effects after experimental 
stroke by distinct mechanisms. These mechanisms could 
include paracrine neuroprotective effects, angiogenesis, 
and immunomodulation although tissue replacement seems 
to be less likely (9). Even if many of these mechanisms are 
presumably mediated by ALDH cells, there is no direct 
evidence that they would exert any ‘cumulative’ effects 
or superior properties over the other, more homogenous, 
cell products described in the literature. It is also not 
clear whether any individual effects might be of particular 
importance in mediating the beneficial effects of ALDH 
cells. Although not being absolutely essential for inclusion 
in an early-stage clinical trial at the moment, incomplete 
knowledge of therapeutic mechanisms is increasingly 
viewed as a short-coming by some regulatory authorities 
such as the European Medical Agency. Hence, there is 
increasing regulatory pressure on investigators and sponsors 
to provide specific knowledge clarifying the therapeutic 
intervention’s modes of action. This is indeed an important 
aspect as such knowledge forms the basis for the design 
of meaningful potency assays. Those would go beyond 
simple phenotypical profiling and a general assessment of 
basic biological properties of the cell products since this 
information may not be sufficient to indicate the presence 
or lack of efficacy for a specific therapeutic application (10). 
Route of ALDH cell administration
Intravenous cell infusion is the most noninvasive delivery 
route for cell products and hence has been predominantly 
chosen for many early-stage stroke trials (5). However, a 
major disadvantage of this form of delivery is that most 
intravenously administered cells become entrapped in 
the capillary networks of the lungs and internal organs, 
dramatically reducing the number of cells reaching the 
target tissue (11). Although the peripheral effects of cells 
are believed to contribute to the beneficial effects evident 
in models of experimental stroke, the presumed lack of 
therapeutic cells in the target tissue (i.e., the brain) is 
generally seen as a drawback in clinical scenarios. Intra-
arterial cell delivery offers a way to circumvent the 
pulmonary circulation at least during the first passage (12), 
but it can be associated with severe complications such as 
cerebrovascular micro-occlusions, particularly when larger 
cell populations are infused (13,14). 
Result overview and safety considerations
The results of the RECOVER-Stroke trial are clear-cut 
and indicate a favorable safety profile of ALDH cells when 
administered intra-arterially after a stroke. The average 
size of ALDH cells is smaller than that of mesenchymal 
stem cells, in general supporting the favorable safety 
profile. However, four patients from the therapy group 
exhibited multiple small, scattered hypointensities in 
follow-up magnetic resonance imaging sessions, potentially 
representing secondary microinfarcts. A more detailed 
inspection of their distribution pattern and bilateral location 
indicated that in three out of four patients the lesions 
were more likely related to the angiographic procedure 
itself rather than ALDH cell administration. These lesions 
were also clinically asymptomatic and did not require 
any additional therapeutic interventions. However, the 
ALDH population contains some mesenchymal stem and 
progenitor cells (7), and therefore, one cannot exclude 
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the possibility that these cells might be at least partly 
responsible for these microinfarcts. Micro-occlusions have 
also been claimed to be related to cell dose (15). Careful 
dose-escalation studies are necessary before embarking on 
efficacy studies not only to detect possible complications 
but also to define the optimal dose for achieving therapeutic 
efficacy. Indeed, a higher dose of intra-arterial autologous 
bone marrow mononuclear cells was related to a better 
outcome in stroke patients, especially when more than 
310×106 cells were injected (16).
The frequency of seizures was much higher in the 
treatment group, raising some safety concerns. Increased 
seizure activity has also been reported after systemic 
cell infusion (17) and may be related to the initial 
hyperexcitability of the ischemic brain (18). It could be 
speculated that the increased frequency of seizures is 
evidence that the transplanted cells reached their intended 
target to activate brain repair and reorganization processes. 
It is possible that by adjusting either the cell dose or timing 
of cell delivery, one might be able to avoid this serious 
complication. In most instances, control of seizures by 
antiepileptic medication must be carefully considered as 
these drugs may impair functional recovery (19). 
Potential reasons for the overall outcome of the 
RECOVER-Stroke trial
The RECOVER-Stroke trial showed neutral results on 
secondary efficacy endpoints addressing the neurological 
outcome. There was a mean difference favoring the 
treatment group which, however, did not translate into 
formal statistical significance due to the relatively large 
standard deviation in both groups and the fact that the 
trial was terminated when it reached the safety endpoint. 
Hence, the secondary neutral outcome does not indicate 
that ALDH cells lack efficacy after a stroke, as other 
design features may have contributed to the neutral 
secondary outcome. One example is the time point of 
cell administration. A major advantage of ALDH cells 
is that they can be isolated from the patient’s own bone 
marrow without requiring a long processing time, in theory 
allowing swift transplantation. The cell processing time in 
the RECOVER-Stroke trial was 2 days, with a number of 
logistical challenges being encountered. Nevertheless, it is 
not completely clear why cell delivery was scheduled at 13–
19 days after the ischemic event, in particular since much 
shorter therapeutic time windows have been utilized in 
most adult stem populations in preclinical trials. Although 
not known at the time of initiation of the RECOVER-
Stroke trial, there is recent clinical evidence also suggesting 
that adult cell therapies have a therapeutic time window 
that is substantially longer than that of established 
recanalization therapies, but is still within the range of 
hours. For instance, the recent MASTERS trial using a 
mesenchymal-like stem cell population from bone marrow 
only achieved its efficacy endpoints when transplantation 
took place within a much earlier time window after stroke 
(<36 h) (20). Interestingly, this time window had already 
been identified in related preclinical datasets. Another 
aspect which may explain the failure to detect efficacy in 
the RECOVER-Stroke trial is the relative heterogeneity 
of its study population that included patients with lacunar 
and territorial infarcts. This heterogeneity might be 
problematic in efficacy-oriented clinical studies although 
strict inclusion and exclusion criteria were applied, as were 
appropriate patient stratification strategies. For instance, 
different locations of a lacunar infarcts as well as differences 
in both location and size of a cortical infarcts can result in 
very different functional deficits. Recent recommendations 
for translational research therefore suggest that there 
should be strictly selected patient subpopulations that are 
as homogenous as possible with respect to stroke type, 
location and functional defects, and ideally reflecting 
the preclinical stroke model in which efficacy has been 
demonstrated (21). Obviously, this kind of selection process 
will slow down recruitment and hence demand a longer 
study duration and more substantial financial resources, 
but might increase the chances for a positive outcome. A 
careful harmonization of preclinical and clinical approaches 
and the selection of the study population becomes even 
more relevant when considering potentially confounding 
aspects such as comorbidities and age (22). Those cannot be 
holistically investigated in preclinical experiments but are a 
major source of effect-masking inter-subject heterogeneity 
in clinical trials. 
Summary and outlook
Undoubtedly,  the RECOVER-Stroke study is  an 
outstanding example due to its well-defined scope and 
methodological rigor. A number of questions remain 
open, but these may well be robustly addressed in future 
downstream phase III investigations. Importantly, all sham 
procedures were carefully planned and conducted ensuring 
the blinding of patients and investigators e.g., numerous 
mock procedures were conducted in the control population. 
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Both the practical and logistic challenges including trial 
design, randomization, blinding and power analysis 
have been described very transparently. The sharing of 
this information and experience will be invaluable for 
investigators planning similar studies. Another valuable 
aspect of the study is that it specifically describes how to 
tackle many of the practical and logistic challenges inherent 
in most cell therapies. Hence, the RECOVER-Stroke trial 
conducted by Savitz et al. may well serve as a role model for 
future early-stage cell therapy clinical trials in stroke.
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